IDEAYA Biosciences (IDYA) Net Cash Flow Growth (1y) (2019 - 2026)
IDEAYA Biosciences (IDYA) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 53.46% |
| 10 | IDEAYA Biosciences | 3.23 Bn | 2.56 Bn | - | -1.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.44% |
| Dec 31, 2025 | 41.18% |
| Sep 30, 2025 | -15.17% |
| Jun 30, 2025 | -120.51% |
| Mar 31, 2025 | 193.72% |
| Dec 31, 2024 | -6,173.63% |
| Sep 30, 2024 | 343.27% |
| Jun 30, 2024 | 106.66% |
| Mar 31, 2024 | -3,389.10% |
| Dec 31, 2023 | 115.61% |
| Sep 30, 2023 | -7.27% |
| Jun 30, 2023 | 685.64% |
| Mar 31, 2023 | 96.20% |
| Dec 31, 2022 | -103.41% |
| Sep 30, 2022 | 193.58% |
| Jun 30, 2022 | 86.65% |
| Mar 31, 2022 | -156.80% |
| Dec 31, 2021 | -78.05% |
| Sep 30, 2021 | 127.15% |
| Jun 30, 2021 | -141.33% |